Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + FOLFOX Neoadjuvant for Gastric/GEJ Cancer
NCT03939962Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoints: R0 resection rate at 16 weeks and pathological complete response rate at 16 weeks. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03939962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939962.